Brought to you by 
Alnylam nets $784.9mm through public stock offering
Nov 2017
Executive Summary
Alnylam Pharmaceuticals Inc. (RNAi therapeutics) netted $784.9mm through the public sale of 6.44mm common shares (including the overallotment) at $125. Proceeds will support future commercialization activities surrounding patisiran (for hereditary ATTR (hATTR) amyloidosis with symptomatic polyneuropathy (previously known as familial amyloidotic polyneuropathy (FAP)); givosiran (acute hepatic porphyrias); and fitusiran (moderate or severe hemophilia A or B).
Deal Industry
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Synthesis Technologies, Production Processes
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alnylam nets $784.9mm through public stock offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice